JAK Monotherapy Shows Efficacy in RA Review

A systematic review found Janus kinase inhibitor monotherapy improved outcomes vs methotrexate or placebo, but direct comparisons with combination therapy were limited.

By
Andrea Surnit
May 22, 2026
4 min

Conexiant

Overview

Janus kinase inhibitor monotherapy demonstrated improved clinical, functional, and radiographic outcomes in rheumatoid arthritis compared to methotrexate or placebo. However, direct comparisons with combination therapy remain limited.

Background

Rheumatoid arthritis (RA) is a chronic autoimmune disorder leading to joint damage and functional impairment. While conventional treatments like methotrexate are standard, many patients require alternative therapies due to inadequate responses. The efficacy of Janus kinase inhibitors as monotherapy presents a potential treatment strategy for selected patients.

Data Highlights

Drug	Response Rate	Study
Upadacitinib 15 mg	52%	SELECT-EARLY
Upadacitinib 30 mg	56%	SELECT-EARLY
Methotrexate	28%	SELECT-EARLY
Baricitinib	58.6%	Phase 3 Trial
Placebo	28.3%	Phase 3 Trial
Filgotinib	76.6%	FINCH 2

Key Findings

JAK inhibitor monotherapy improved ACR 50% response rates compared to methotrexate in methotrexate-naive patients.
Upadacitinib maintained low disease activity in approximately 42% of patients over 260 weeks.
Baricitinib showed higher response rates than placebo in patients with inadequate response to methotrexate.
Filgotinib demonstrated efficacy both as monotherapy and in combination with methotrexate.
Infections were the most commonly reported adverse events across studies.
Safety interpretations should consider broader class concerns, including risks of major adverse cardiovascular events and malignancies.

Clinical Implications

JAK inhibitor monotherapy may be a viable treatment option for patients with rheumatoid arthritis who cannot tolerate methotrexate or other conventional agents. Individualized decision-making is essential, considering the potential benefits and risks associated with this treatment strategy.

Conclusion

The review supports the efficacy of JAK inhibitor monotherapy in rheumatoid arthritis, although further research is needed to clarify its role compared to combination therapies.